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ABSTRACT
Hedgehog signaling controls proliferation of cerebellar granule cell precursors 
(GCPs) and its aberrant activation is a leading cause of Medulloblastoma, the most 
frequent pediatric brain tumor. We show here that the energy sensor AMPK inhibits 
Hh signaling by phosphorylating a single residue of human Gli1 that is not conserved 
in other species.
Studies with selective agonists and genetic deletion have revealed that AMPK 
activation inhibits canonical Hh signaling in human, but not in mouse cells. Indeed we 
show that AMPK phosphorylates Gli1 at the unique residue Ser408, which is conserved 
only in primates but not in other species. Once phosphorylated, Gli1 is targeted for 
proteasomal degradation. Notably, we show that selective AMPK activation inhibits 
Gli1-driven proliferation and that this effect is linked to Ser408 phosphorylation, 
which represents a key metabolic checkpoint for Hh signaling.
Collectively, this data unveil a novel mechanism of inhibition of Gli1 function, 
which is exclusive for human cells and may be exploited for the treatment of 
Medulloblastoma or other Gli1 driven tumors.
INTRODUCTION
Sonic Hedgehog (Shh) pathway is a critical 
regulator of embryonic development, cell proliferation 
and stem cell fate. In the cerebellum, Shh signaling 
promotes postnatal proliferation of cerebellar granule cell 
progenitors (GCPs) [1], and its deregulation at this level 
causes Medulloblastoma (MB), the most frequent brain 
malignancy of the childhood [2, 3].
Shh ligand binds to the inhibitory receptor 
Patched (Ptch), thus relieving its inhibitory effect on the 
transmembrane transducer Smoothened (Smo). These 
events initiate a cascade of intracellular processes that lead 
to the activation of the Gli transcription factors (Gli1, Gli2 
and Gli3). A key event for Gli activation is the dissociation 
from the cytoplasmic inhibitor Sufu [4]. Activation of 
Gli promotes the execution of transcriptional programs, 
regulating cell proliferation, survival, metabolism and 
migration. The aberrant activation of Shh pathway 
observed in MB and other tumors is due to genetic 
mutations of pathway components or to autocrine or 
paracrine ligand-dependent mechanisms of activation [5].
The understanding of the key role of Hedgehog (Hh) 
signaling in tumorigenesis has prompted investigation, 
aimed at identifying molecules targeting this pathway. 
Different drugs have been generated and the majority of 
them are Smo inhibitors. However, these molecules are 
inactive in case of mutations occurring downstream of 
Smo (i.e. Sufu or Gli mutations). Furthermore, clinical 
trials in patients and animals with tumors driven by 
mutations of Ptch or Smo have shown that, after a good 
initial response, tumor cells quickly acquire resistance 
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to Smo antagonists. For these reasons it is now believed 
that alternative approaches, preferably targeting Gli, are 
required [6, 7].
A few Gli inhibitors, acting directly or indirectly, 
have been generated in recent years and some of them 
have shown a good specificity and efficacy in preclinical 
trials. However, further pharmacological validations and 
studies are still required before these compounds can 
enter clinical trials. An alternative approach could be 
the research of drugs of known clinical efficacy with the 
ability to target Gli or its downstream-regulated pathways.
Recent findings have shown that, during 
Hh-dependent proliferation, Gli transcription factors 
regulate transcriptional programs in normal and tumor 
cells, switching their metabolism toward aerobic glycolysis 
and lipogenesis and increasing the utilization of glucose 
and lipids [8–10]. This suggests that the availability of 
these nutrients may represent a key determinant to favor 
or prevent Hh-driven cell proliferation. A key sensor 
and regulator of nutrient availability is the AMP kinase 
(AMPK), which consists of three different subunits: alpha, 
beta and gamma [11]. Under low nutrient conditions, the 
intracellular AMP/ATP ratio raises and activates AMPK 
through the binding of AMP to the gamma subunit and 
release of the alpha, catalytic subunit [12]. This activates a 
coordinated compensatory response, aimed at restoring the 
intracellular ATP levels through increased mitochondrial 
activity and biogenesis, activation of autophagy and 
inhibition of energy demanding processes, such as 
cell proliferation [13]. In this view, energy-demanding 
developmental programs, associated to rapid tissue growth 
and nutrient consumption, such as the Hedgehog-regulated 
processes, could be ideal targets to be turned off under low 
nutrient conditions.
We report here the identification of a novel 
mechanism of inhibition of the Hh signaling at a 
downstream level, by the energy sensor AMPK. Given the 
availability of drugs activating this kinase, these findings 
may have relevant implications for the treatment of MB 
and other tumors associated to aberrant activation of the 
Hh signaling.
RESULTS
AMPK inhibits Hh signaling only in human cells
To determine whether the intracellular energy 
sensing machinery and the developmental Hh signaling 
are functionally connected, we tested the effect of different 
AMP Kinase (AMPK) agonists in Hh-stimulated cells. 
To this end, we used the two commercially available 
Hh-responsive cells: mouse fibroblasts NIH3T3 [14] and 
human medulloblastoma DAOY cells [15, 16]. Both cell 
lines were treated at early (6 hours) and late (24 hours) 
time points with the Smo agonist Sag, which activates Hh 
signaling [17], monitoring the mRNA levels of Gli1, a 
standard Hh target gene.
We first measured the effect of three commonly used 
AMPK activators: AICAR, which is converted in cells into 
ZMP that binds the alpha subunit of AMPK in place of 
AMP [18]; 2-deoxyglucose (2DG) and Metformin, which 
block glycolysis and mitochondrial function respectively, 
thereby leading to elevations of the AMP/ATP ratio [19].
Treatment with the three drugs robustly repressed 
Sag-induced Gli1 mRNA levels in both cell lines at both 
time points (Figure 1A, Supplementary Figure S1A). 
To verify that this effect was mediated by AMPK 
we used the double AMPK alpha knockout MEF cells, 
lacking both alpha1 and alpha2 catalytic subunits of the 
kinase [20]. Interestingly, AICAR, 2DG and Metformin 
still inhibited the Hh-dependent transcriptional output, 
indicating that the observed inhibitory effect was 
independent of AMPK (Figure 1B). We then tested 
the effect of A-769662, a compound that was shown to 
bind the beta subunit and selectively activate AMPK, 
without off target effects [19, 21]. As shown in Figure 1C, 
incubation of Sag-treated cells with this drug for 24 hours 
did not have any significant effect in Sag-treated mouse 
fibroblasts, whereas it robustly inhibited the signaling in 
human DAOY cells. Knockdown of both alpha subunits 
of AMPK with shRNAs in DAOY cells prevented the 
A-769662 inhibition (Figure 1D), thus confirming that this 
effect was bona fide AMPK-dependent.
To study at what level of the Hh signaling AMPK 
exerts its inhibitory role, we tested the effect of A-769662 
on Sufu-deficient DAOY cells. In the absence of Sufu, the 
transcriptional activity of the Gli transcription factors is 
upregulated with consequent increase of Gli-target gene 
expression, which is independent of upstream receptor 
activation [22].
Ablation of Sufu increased Gli1 mRNA levels and 
this effect was still inhibited by A-769662, indicating that 
AMPK exerts its inhibitory effect at downstream level 
(Figure 1E, Supplementary Figure S1B).
Thus, these data demonstrate that AMPK activation 
inhibits Hh signaling only in human cells, by targeting a 
downstream component of the pathway.
AMPK phosphorylates Gli1 at Ser408
We tested the possibility that AMPK could directly 
phosphorylate human Gli1, Gli2 and Gli3 by performing 
an in vitro AMP kinase assay. We expressed human 
Flag-tagged Gli1-3 in HEK293T cells and performed Flag 
immunoaffinity purification, followed by the incubation of 
the eluted proteins with purified AMPK and 32P -labeled 
gamma ATP.
As shown in Figure 2A, only Gli1 efficiently 
incorporated 32P in the presence of AMPK, whereas 
Gli2 and Gli3 did not. The same evidence was obtained 
in vivo in HEK293T cells, where the CAMKK2/AMPK 
axis is constitutively active and can be inhibited with the 
CAMKK2 inhibitor STO609 ([23] and Supplementary 
Figure S2A). After transfection of Flag-tagged Gli1-3 in 
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Figure 1: AMPK inhibits Hh signaling only in human cells. (A) NIH3T3 (left) and human DAOY (right) cells were treated 
with Sag or Dmso, AICAR (2 mM), 2-deoxyglucose (2DG, 25 mM) or Metformin (5 mM) as indicated, for 6 hours. Levels of Gli1 
mRNA were analyzed by quantitative PCR. (B) Wild type or AMPK−/− MEF cells were treated with Sag or Dmso, AICAR (2 mM), 
2-deoxyglucose (2DG, 25 mM) and Metformin (5 mM) as indicated for 6 hours. Gli1 mRNA levels were evaluated by quantitative PCR. 
The experiment was repeated three times. (C) NIH3T3 (top) and DAOY cells (bottom) were treated with Sag or Dmso, and with A-769662 
(25 μM) for 24 hours. Gli1 mRNA levels were evaluated by quantitative PCR. (D) (Top) Quantitative real time PCR on AMPK-deficient 
DAOY cells. DAOY cells were infected with lentiviruses expressing shRNA targeting both α1 and α2 AMPK subunits (shAMPK) or with 
non-targeting shRNA. Cells were treated with Sag or Dmso and A-769662 (25 μM) for 24 hours as indicated. Gli1 mRNA levels were 
assessed. Knockdown efficiency was analyzed by immunoblotting with the indicated antibodies (bottom). (E) DAOY cells were transfected 
with siRNA against Sufu (siSufu), or with non-targeting siRNA (siCtr); cells were then treated with A-769662 (25 μM) or Dmso and Gli1 
mRNA levels were measured by quantitative real time PCR. Results are expressed as mean and SD of three independent experiments, each 
performed in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001 and ns (not significant) for the indicated comparisons.
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these cells, IP and immunoblot with an antibody reacting 
against phosphorylated AMPK substrates, phosphorylation 
of Gli1, but not Gli2 or Gli3, was readily detected 
(Figure 2B, Supplementary Figure S2B). 
Consistent with the observed inhibitory effect of 
AMPK agonists, AMPK overexpression inhibited Gli1, 
but not Gli2 transcriptional activity in luciferase assays 
(Figure 2C) in human DAOY cells. Also, expression of 
human Gli1 in mouse fibroblasts increased Gli-Luc reporter 
activity and this effect was significantly inhibited by 
A-769662, further demonstrating that AMPK specifically 
represses human Gli1 (Supplementary Figure S2C). Thus, 
AMPK phosphorylates and inhibits Gli1 function.
To map the AMPK phosphorylated residue/s, we tested 
the phosphorylation of several Gli1 fragments (Figure 2D) 
in HEK293T cells.  Analysis of the phosphorylation status 
of the different mutants led to the identification of a 200 aa 
region, spanning from aa 228 to aa 413 that was efficiently 
phosphorylated (Figure 2D, Supplementary Figure S2D), 
whereas the other regions were not. Sequence analysis of the 
228–413 region showed the presence of a consensus AMPK 
site surrounding the Serine 408 (Figure 2E). Interestingly, 
Ser408 residue is conserved only in primates, but not in 
mouse or other species, thus providing an explanation to the 
above-observed inhibitory effect of AMPK on Hh signaling 
in human, but not mouse cells.
We mutated Serine 408 to Alanine and observed that 
the phosphorylated Gli1 band completely disappeared in 
both in vivo and in in vitro kinase assays (Figure 2F–2H), 
indicating that Ser408 is the only AMPK phosphorylated 
residue of Gli1.
Notably, in Gli-Luc reporter assays the S408A 
mutant displayed higher transcriptional activity than WT 
Gli1 and was no longer inhibited by AMPK, supporting 
that this single residue is completely responsible of the 
effect of AMPK (Figure 2I). Further confirming this 
observation, a phosphomimetic S408E mutant showed 
significantly reduced transcriptional activity (Figure 2J).
To understand the physiological relevance of 
this modification, we generated and validated a rabbit 
antisera reacting against phosphorylated Gli1 Ser408 
(Supplementary Figure S2E). Activation of AMPK with 
A-769662 increased ectopic and endogenous Ser408 
phosphorylation (Figure 2K, 2L), but not of its mutant, 
and the AMPK inhibitor Compound C (CC) prevented this 
modification (Supplementary Figure S2F). Thus, AMPK 
phosphorylates Gli1 at Ser408, thereby inhibiting its activity.
Ser408 phosphorylation promotes Gli1 
degradation
We next sought to understand how Gli1 Ser408 
phosphorylation exerts its inhibitory effect. 
Previous studies on the mechanisms of AMPK-
mediated inhibition have documented two recurrent mode 
of action upon phosphorylation of substrates: 1) binding to 
14-3-3 proteins and cytoplasmic sequestration [24] and 2) 
targeting to proteasomal degradation and destabilization 
[25, 26].
Since an inhibitory binding between Gli1 and 
14-3-3 epsilon proteins has been reported [27], we first 
tested the possibility that AMPK could increase this 
association by performing coimmunoprecipitation studies. 
We confirmed the association between Gli1 and 14-3-3, 
but did not observe any increased affinity following 
A-769662 treatment ( Figure 3A). Consistently, neither the 
binding affinity for 14-3-3 (Figure 3B), nor the intracellular 
compartmentalization of S408E mutant differ from that of 
WT Gli1 (Figure 3C) thus ruling out this mechanism.
We next addressed the possibility that AMPK 
could regulate Gli1 turnover.  DAOY cells were first 
treated with Sag to increase Gli1 protein levels and 
then incubated with A-769662 for 6 and 24 hours, 
monitoring Gli1 protein and mRNA levels. After 6 hours 
of incubation with A-769662, we observed that Gli1 
protein levels were reduced, whereas the mRNA levels 
were not changed (Figure 3D, left). After 24 hours both 
mRNA and protein were decreased (Figure 3D, right), 
suggesting that, following AMPK phosphorylation, Gli1 
is first destabilized and then the mRNA levels decrease as 
a consequence of its degradation. Both the proteasomal 
inhibitor MG132 (Figure 3E) and the lentiviral shRNA-
mediated knockdown of AMPK  (Figure 3F) prevented the 
A-769662 mediated downregulation of Gli1, indicating a 
proteasome-mediated, AMPK-dependent mechanism of 
degradation.
To confirm this observation, DAOY cells 
expressing WT or S408A mutant Gli1 were incubated for 
different time points with the protein synthesis inhibitor 
cycloheximide in the presence of A-769662 or vehicle. As 
shown in Figure 3G and Supplementary Figure S3A–S3B, 
the degradation rate of WT Gli1 was significantly enhanced 
by A-769662, while the AMPK-insensitive S408A mutant 
was more stable and not affected by the treatment. 
Consistently, A-769662 increased the ubiquitination of 
WT but not of Ser408A Gli1 mutant, whereas the AMPK 
inhibitor Compound C (CC) inhibited this modification 
(Figure 3H, Supplementary Figure S3C).
Collectively, these data demonstrate that AMPK 
phosphorylation at Ser408 promotes Gli1 turnover.
Targeting Ser408 reduces proliferation of MB cells
Having found that AMPK inhibits Hh signaling via 
Gli1 phosphorylation, we next sought to understand if this 
mechanism could be exploited to limit Hh-dependent MB 
growth.
Since AMPK may inhibit cell proliferation with 
multiple mechanisms, recruiting different substrates 
[24], we addressed the specific involvement of Gli1 
Ser408 phosphorylation by generating DAOY cell 
lines stably expressing Gli1 WT or the phosphorylation 
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Figure 2:  AMPK phosphorylates human Gli1 at Ser408. (A) Flag-Gli1, Flag-Gli2 and Flag-Gli3 proteins were expressed in 
HEK293T cells, and immunoprecipitated from whole cell lysates with Flag antibody. Eluted proteins were then incubated with catalytically 
active AMPK protein. 32P incorporation levels were assessed by autoradiography. Gli proteins expression was evaluated by western blot 
analysis with Flag antibody. (B) HEK293T cells were transfected with Flag-Gli1, Flag-Gli2 and Flag-Gli3 and overexpressed proteins 
were purified by immunoprecipitation. Phosphorylation was assessed by immunoblotting with anti-phospho serine AMPK substrate (P-Ser 
AMPK Sub) antibody. Filters were reprobed with Flag antibody to detect immunoprecipitated Gli protein levels. (C) Gli-Luc reporter assay 
showing the effect of  AMPK overexpression on Flag-Gli1 and Flag-Gli2 transcriptional activity in DAOY cells. Results are expressed 
as Luciferase/Renilla fold change relative to control sample. (D) Left, western blot analysis of immunoprecipitates from HEK293T cells, 
transfected with plasmids encoding full-length Flag-tagged Gli1 or indicated fragments. Phosphorylation of the various Gli1 regions was 
assessed. Flag-CRTC2 was used as positive control. Right, schematic representation of Gli1 fragments. Red: phosphorylated fragments. (E) 
Protein sequence alignment of primates and murine Gli1, showing a conserved AMPK phosphorylation motif around Serine 408 (Ser408). 
Optimal AMPK motives are shown. (F) In vivo phosphorylation assay in HEK293T cells. Flag-tagged WT or S408A mutant Gli1 proteins 
were overexpressed and immunoprecipitated. Phosphorylation was assessed by immunoblot with anti-phospho serine AMPK substrate 
(P-Ser AMPK Sub)  antibody. WT and mutant Gli1 protein levels in immunoprecipitated samples and cell lysates (Input) was carried 
out with Flag antibody. (G) Kinase assay on WT and S408A mutant Gli1 proteins, with or without active AMPK protein. Flag-Gli1 WT 
and S408A mutant were expressed in HEK293T cells and immunoprecipitated. 32P incorporation was revealed by autoradiography. Gli1 
proteins expression was evaluated by western blot analysis. (H) In vitro AMPK-phosphorylation assay of GST alone, recombinant GST-Gli1 
228–413 WT or S408A mutant. Incorporation of 32P was determined by autoradiography and the protein levels were detected by Coomassie 
blue staining. (I) Gli-Luc reporter assay showing the effect of AMPK on Gli1 WT and S408A mutant activity. Results are expressed as 
Luciferase/Renilla fold change relative to control sample. (J) Transcriptional activity of Gli1 WT versus non-phosphorylatable and phospho-
mimetic mutants. Results are expressed as Luciferase/Renilla fold change relative to control sample. (K) HEK293T cells were transfected 
with Flag-tagged Gli1 WT and S408A mutant and treated with A-769662 (25 μM) for 1 hour. Cell extracts were immunoprecipitated 
with anti-Flag antibody and Serine 408 phosphorylation was revealed with a phospho-Serine 408 (P-Ser408) antibody. Immunoprecipitated 
Gli1 protein levels are shown. Western blotting of cell lysates (Input) was performed with Flag, phospho-ACC (P-ACC) and tubulin 
antibodies. (L) Serine 408 phosphorylation of endogenous Gli1 in DAOY cells. Cells were treated with A-769662 for 1 hour and Gli1 
protein was immunoprecipitated from whole cell lysates. Immunoprecipitated Gli1 protein levels are shown. Results are expressed as mean 
and SD of three independent experiments, each performed in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001 and ns (not significant) for 
the indicated comparisons.
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Figure 3: AMPK-mediated phosphorylation at Ser408 targets Gli1 to proteasomal degradation. (A) Co-immunoprecipitation 
assay on DAOY cells transfected with plasmids expressing  Flag-Gli1 and HA-14-3-3 epsilon. Cells were treated with or without A-769662 
for the indicated times and Flag-Gli1 was immunoprecipitated. Binding was evaluated by western blotting of eluted proteins using Flag 
and HA antibodies. (B) As in A), DAOY cells were transfected with plasmids expressing Flag-Gli1 WT or S408A and S408E mutants, and 
HA-14-3-3 epsilon. After co-immunoprecipitation, immunocomplexes were detected with Flag and HA antibodies. (C) DAOY cells were 
transfected with Flag-WT and mutant Gli1 proteins. Nuclear and cytoplasmic fractions were analyzed by western blotting. Purity of nuclear 
and cytoplasmic fractions was evaluated by laminin and tubulin staining, respectively. (D) (Top) Quantitative real time PCR analysis of 
Gli1 mRNA levels on DAOY cells treated with or without Sag for 36 hours, and with or without A-769662 (25 μM) for 6 or 24 hours. 
(Bottom) Western blot analysis of cell lysates showing Gli1 and tubulin protein levels. (E) DAOY cells were treated with the proteasome 
inhibitor MG132 (50 μg/mL), and  with the AMPK agonist A-769662 (25 μM), for 6 hours. The total cell lysates were analyzed by western 
blot using Gli1 antibody. Tubulin, loading control. (F) DAOY cells, infected with lentiviruses expressing shRNA targeting both α1 and α2 
AMPK subunits (shAMPK) or with non-targeting shRNA (shCtr), were treated with Sag for 36 hours, and with A-769662 (25 μM) for 6 
hours. Western blot analysis of cell extracts shows AMPK and tubulin levels. (G) DAOY cells were transfected 24 hours with Flag-Gli1 WT 
and S408A mutant and pre-treated with cycloheximide (CHX, 30 μM) for 20 minutes to inhibit protein synthesis. Cells were then incubated 
with or without A-769662 (12.5 μM) for the indicated time points. Western blots were performed on whole cell lysates using Flag antibody 
to detect Gli1 protein levels. Tubulin is shown as a loading control. (H) Flag-Gli1 WT and S408A mutant were co-transfected in DAOY 
cells with HA-Ub. Cells were pre-treated with MG132 (50 μg/mL) and incubated with A-769662 (25 μM) for 3 hours. Cellular lysates were 
immunoprecipitated with Flag antibody and ubiquitination revealed by HA-Ub western blotting. The blot was reprobed with Flag antibody 
to detect Gli1. Results are expressed as mean and SD of at least three independent experiments, each performed in triplicate. **P < 0.01 
and ns (not significant) for the indicated comparisons.
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defective S408A or the phosphomimetic Ser408E 
mutants. As previously observed [28], stable expression 
of Gli1 caused a significant increase of colony 
formation and cell proliferation rate. Compared 
to cells expressing WT Gli1, the proliferation was 
significantly increased in cells expressing Ser408A 
mutant and decreased in those expressing Ser408E 
(Figure 4A, 4B), thus supporting the inhibitory 
role of Ser408 phosphorylation on Gli1-dependent 
proliferation. We next tested whether AMPK activation 
could counteract MB cell growth by specifically targeting 
Gli1 Ser408.  Notably, as shown in Figure 4C, while 
treatment with A-769662 caused a significant inhibition 
of the proliferation rate in cells expressing WT Gli1, it 
failed to inhibit the proliferation driven by the S408A 
mutant. Therefore, this latter evidence demonstrates that 
the inhibitory effect of AMPK agonists on Gli1-driven 
proliferation requires the integrity of Ser408, which 
represents the key regulated checkpoint of this mechanism 
(Figure 4D). Similar data were obtained using the colon 
cancer cell line HT29 (Supplementary Figure S4), 
demonstrating that the Ser408-dependent proliferation 
effect is not cell-type specific, but rather Gli1-specific.
DISCUSSION
Inhibition of Gli transcription factors is emerging as 
a potential valuable strategy for the treatment of tumors 
characterized by an “addiction” to Hh signaling. Indeed, 
the occurrence of resistance observed in patients treated 
with Smo antagonists has dampened the enthusiasm 
for this class of inhibitors and opened a new era of 
investigation, aimed at the identification of inhibitors 
acting at a downstream level.
In this report we demonstrate that AMPK is a 
potential weapon to achieve this goal, thanks to the ability 
of this kinase to directly phosphorylate and inhibit the 
downstream effector Gli1.
Interestingly, many drugs commonly used as 
AMPK agonists (e.g. AICAR, biguanides, 2DG) inhibit 
Hh signaling even in the absence of the kinase, as 
demonstrated by the persistence of inhibition in AMPK−/− 
MEF cells. The off target effects of these compounds were 
already know and attributed to the regulation of other 
substrates, such as the mTORC regulator Rag GTPase or 
the mitochondrial respiratory-chain complex 1 [29]. While 
it is not surprising that the inhibition of protein synthesis 
or mitochondrial function may impact proliferation or 
survival in normal or tumor cells, the molecular basis of 
the AMPK-independent inhibition on Hh signaling exerted 
by these drugs is still an open issue.
The use of a specific AMPK agonist or knockdown 
approaches have allowed us to demonstrate that AMPK 
is a powerful inhibitor of Gli1 function, but only in 
human cells. This is due to the presence of a consensus 
AMPK site, Ser408, which is conserved only in primates, 
reasonably representing a mechanism acquired during 
evolution that enables the Hh pathway to directly respond 
to energy stress.
We demonstrate that activation of AMPK promotes 
Gli1 ubiquitination and proteasomal degradation. A 
similar mechanism of inhibition was described previously 
[26], where it was shown that AMPK phosphorylates the 
Glut1 inhibitor TXNIP, thereby targeting this protein for 
degradation with consequent increase of glucose influx. 
Interestingly, it was proposed that, upon phosphorylation, 
the ubiquitination/degradation of TXNIP is mediated by 
Itch, an E3 ubiquitin ligase. Since Itch has been shown to 
regulate Gli1 stability [30, 31] it is possible that this ligase 
is involved in the AMPK-dependent degradation of Gli1.
The ability of AMPK to regulate Hh signaling 
was previously observed in hepatocellular carcinoma 
cells [32], although the underlying mechanism was not 
understood. 
A very recent report showed the ability of AMPK 
to phosphorylate and inhibit Gli1 [33]. However, the 
selectivity of the AMPK effect for only human Gli1 was 
not demonstrated, neither was reported the ability of the 
different drugs, such as AICAR and Metformin, to exert 
their inhibitory function even in the absence of AMPK. 
Interestingly, in addition to Ser408 two other 
residues, not matching with any AMPK consensus 
sequence, were identified in that report: S102 and T1074. 
However, we could not detect in our assays any additional 
phosphorylated residue, beside Ser408. A possible 
explanation for this discrepancy could be that we did not 
overexpress the kinase together with Gli1, but used the 
constitutive activity of endogenous AMPK in HEK293T 
cells. Moreover, we could not detect any residual 
inhibitory activity of AMPK on Gli1 in the absence of 
S408, further supporting the functional importance of this 
site.
These aspects are relevant since the selectivity of 
AMPK for human Gli1 precludes further preclinical 
studies, evaluating the effect of selective AMPK agonists 
in mouse or other animal models of Hh dependent tumors. 
Studies with appropriate cellular models and clinical 
approaches are now required to evaluate the relevance of 
this mechanism for tumor treatment.
In conclusion, we have unmasked a functional 
connection between energy sensors and a tumor regulator, 
which pave the way to future studies aimed at validating 
the pathophysiological role of this mechanism in MB and 
other Hh-dependent tumors.
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Figure 4: AMPK-mediated Ser408 phosphorylation inhibits Gli1 driven MB cell proliferation. (A) (Left) DAOY cells stably 
expressing Flag-Gli1 WT, S408A and S408E mutants were seeded on 6-well plates and grown for 2 weeks. Colonies (larger than 1,5 mm) 
were counted. Middle, representative images of the colony assay. (Right) The amounts of the expressed Gli1 proteins were analyzed 
by immunoblotting with Flag antibody. Tubulin, loading control. (B) Proliferation rate of DAOY stable clones. Each clone was seeded 
in triplicate and counted at the indicated times. (C) As in B), cells were treated with A-769662 (25 μM) and counted at the indicated 
time points. (D) Model of the AMPK/Gli1 mediated mechanism of Hedgehog pathway regulation. Under normal conditions, Gli1 binds 
to Hedgehog target genes promoters and activates their expression to regulate proliferative and developmental processes. Activation of 
AMPK by drugs or energy stress phosphorylates Gli1, leading to its degradation. With this mechanism, AMPK inhibits Hedgehog pathway 
and Hedgehog-dependent events. Results are expressed as mean and SD of three independent experiments, each performed in triplicate. 
*P < 0.05 and **P < 0.01 for the indicated comparisons.
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MATERIALS AND METHODS
Cell culture
NIH3T3 and HEK293T were cultured as previously 
described [34]. Human medulloblastoma DAOY cells 
were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA, USA) and cultured 
in MEM with Earl’s salts containing 10% FBS, 2% 
Penicillin-Streptomycin, 1% Glutamine, 1% Non Essential 
Aminoacids, 1% Sodium Pyruvate. AMPK double 
knockout (AMPK−/−) MEF cells were kindly provided by 
Benoit Viollet and cultured as described [20]. 
Drugs and drug treatments
Sag was purchased from Adipogen Life Sciences 
(Liestal, Basel, Switzerland). For Hh pathway activation, 
DAOY cells were incubated overnight in serum-free 
medium, containing 1% BSA, and then exposed to Sag 
(200 nM) for the indicated time points.
AICAR was purchased from Cayman Chemicals, 
A-769662 from Tocris Bioscience, Metformin and 
2-deoxyglucose from Sigma-Aldrich. 
DAOY cells were pre-treated with MG132 
(Calbiochem, Merk Group) to prevent protein degradation, 
and then incubated with A-769662. Cells were treated with 
cycloheximide (CHX, Sigma-Aldrich) and A-769662 as 
described in the text. The total cell lysates were analyzed 
by western blot using the indicated antibodies.
Transfections, luciferase, binding assays, 
ubiquitination and kinase assays 
Transfections and ubiquitination assays were 
performed as previously described [28, 35]. GST proteins 
were expressed in E. coli and purified with standard 
techniques. Luciferase assays were performed as described 
previously [28, 36].
For in vivo phosphorylation assay, HEK293T cells, 
transfected with full-length Flag Gli1 or Ser408A mutant, 
were lysed with the IP-Tris lysis buffer (50 mM TrisHcl 
pH 7.5, 1mM EGTA, 1mM EDTA, 0.5%Triton-X100, 10 
mM sodium β-glycerophosphate, 1 mM Na3VO4, 50 mM 
NaF, 5mM Na4P2O7, 0.1% (v/v) DTT, 0.15M NaCl, 
10% Glicerol, 0.1 mM PMSF), and immunoprecipitated 
with anti-Flag-Agarose (Sigma, A2220 IP 20 μl). 
After immunoblot, phosphorylation was detected with 
phospho-(Ser/Thr) AMPK Substrate antibody (#5759 Cell 
Signaling, 1:1000) or with the specific phospho-Serine 408 
antibody (1:1000).
The in vitro 32P-labeled incorporation/radioactive 
phosphorylation assay was performed as previously 
described [37]. Recombinant Gli1 or full-length Flag 
Glis were incubated for 20 minutes at 30°C with 20 μl 
1X Kinase Buffer (200mM Tris pH 7.5, 50 mM 
β-glycerophosphate, 2 mM Na4P2O7) supplemented with 0.5 
mM DTT, and 10 μl M-ATP buffer (300 μM ATP, 300 μM 
AMP, 66 mM MgCl2, 33 mM MnCl2), with or without 
0.1U recombinant AMPK (Millipore, #14–840) and 10 μCi 
[γ-32P] ATP. The reaction was terminated by the addition 
of sample buffer (60 mM Tris, 2% SDS, 6% glycerol, 
1% β-mercaptoethanol, and 0.002% bromophenol 
blue). Samples were separated by SDS-PAGE, and 
phosphorylation was detected by autoradiography.
Quantitative PCR and RNA interference
Quantitative real time PCR was performed as 
previously described [28]. Briefly, total RNA was isolated 
with Trizol (Invitrogen) and reverse-transcribed with 
Superscript II reverse transcriptase and random hexamers 
(Invitrogen). A reaction mixture containing cDNA 
template, SensiFast Sybr Lo-Rox master mix (Bioline) 
and primer probes mixture was amplified using suggested 
Q-PCR thermal cycler parameters. Amplification primers 
are listed in Supplementary Table S1. Each amplification 
reaction was performed in triplicate and the average of the 
three threshold cycles was used to calculate the amount 
of transcript in the sample (using ViiA™ 7 software, Life 
Technologies, USA). Results were expressed as fold 
induction relative to control samples using the ΔΔCt 
method. Hprt was used as endogenous control.
siRNA transfections were performed by incubating 
DAOY cells with Hyperfect (Qiagen), according to the 
manufacturer’s instructions. Briefly, siRNA were diluted 
in Optimem medium and supplied with the transfection 
reagent; the mixture containing the siRNA/Hyperfect 
complexes was then added to the cells, previously seeded 
in Optimem medium. After 6 hours, the transfection 
media was removed, and new fresh complete media was 
added. The day after transfection, a second transfection 
was performed and the cells were incubated for further 
24 hours. Cells were then treated as indicated in the 
text. Human siSufu was purchased from Dharmacon 
(M-015382-00).
Lentiviral-mediated shRNA knockdown
Subconfluent HEK293T cells were cotransfected 
by calcium phosphate precipitation with 20 μg of 
PLKO.1, 15 μg pCMV-R 8.74 and 10 μg pMD.G, to 
produce shAMPKα1 or shAMPKα2 or non-targeting 
lentiviruses. Supernatant was collected 24 and 48 hours 
later. Virus titer was determined using the HIV-1 p24 
ELISA (NEK050B001KT, Perkin-Elmer), following 
manufacturer’s instructions. pLKO.1 vectors used for 
lentiviral production were obtained by Sigma (MISSION 
shRNA SIGMA): Ampkα1 (TRC0000000861), Ampkα2 
(TRC00000002171) and shc002 (control shRNA). To 
perform the lentiviral transduction, DAOY cells were 
seeded overnight in 12-well plates. The day after, 5 MOI 
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of lentivirus were complexed with 5 mg/ml polybrene 
(Santa Cruz Biotechnology), added to the cells and left 24 
hours before being removed and replaced with standard 
medium. Knockdown efficiency was monitored by AMPK 
western blotting.
Cell proliferation and colony formation assays
To obtain DAOY stable lines, expressing wild type 
or mutant Gli1, cells were transfected with Lipofectamine 
and Plus reagent (Invitrogen), according to the 
manufacturer’s recommendations.
After 48 hours from transfection, G418 (Cellgro) was 
added to the media, to a final concentration of 800 µg/ml. 
After 2–3 weeks of selection, colonies were picked and 
expanded. Throughout all the experiment, no changes in 
exogenous protein expression level, were detected.
Stable lines were then used to perform cell 
proliferation and colony formation assays [36]. For 
proliferation assays, 3 × 104 cells were seeded in each 
12 Multiwell plate well; cell proliferation was assayed 
every day through Trypan Blue cell count for three 
consecutive days. Each experimental point was performed 
in triplicate and each experiment was performed at least 
three times. To perform colony-formation assays, DAOY 
stable lines were detached, diluted to a concentration of 
2 × 102 for each 60mm dish, and grown with G418 for 
10–14 days to allow colony formation. Colonies were 
stained with Coomassie Brilliant Blue, and colony 
numbers and sizes were measured. Each experimental 
point represents a triplicate and the results shown are 
representative of at least three independent assays.
Western blotting and immunoprecipitation 
assays
Lysates where separated by SDS–polyacrylamide 
gel electrophoresis, followed by subsequent western blot 
analysis. Gels were blotted on Protran Nitrocellulose 
Hybridization Transfer Membrane (PerkinElmer) 
and incubated with the indicated primary antibody, 
then with horseradish peroxidase-coupled secondary 
antibody. Detection of the horseradish peroxidase signal 
was performed using Western Lightning Plus ECL 
(PerkinElmer) according to the manufacturer’s protocol.
Densitometry was performed on acquired 
images using ImageJ software (Rasband, W.S., 
ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, http://imagej.nih.gov/ij/, 1997–2015). 
Immunoprecipitation assays were performed as previously 
described [28].
Cellular fractionation
Cellular fractionation was performed according to 
a previous report [38] with some modifications. Cellular 
pellets were resuspended in 100 µl buffer A (10 mM Hepes 
pH 7.4, 10 mM KCl, 10 mM NaCl, 0.1 mM EDTA, 0.1 mM 
EGTA, 1 mM DTT, 0.5 mM PMSF). After 15 minutes of 
incubation, 6 µl of NP40 (0.6%) were added and lysates 
were vortexed 10 sec and centrifuged at 11,000g for 30 sec. 
The supernatant containing the cytoplasmatic extract 
was centrifuged at 11,000g for 20 minutes, while nuclear 
pellets were washed in 500 µl of Buffer B (20 mM Hepes 
pH 7.4, 20% Glycerol, 100 mM KCl, 1mM EDTA, 1 mM 
DTT, 0.5 mM PMSF, 10 mg/mL leupeptin), incubated for 
15 minutes on ice and, after addition of 1% NP40, vortexed 
for 10 sec and centrifuged at 11,000 g for 30 sec. Nuclear 
pellets were resuspended in 50 µl of Buffer C (20 mM 
Hepes pH 7.4, 20% Glycerol, 400 mM NaCl, 1mM EDTA, 
1mM EGTA, 1mM DTT, 0.5 mM PMSF, 10mg/mL 
leupeptin), incubated on ice for 20 minutes, vortexed, and 
centrifuged at 13,000 g for 10 minutes.
Antibodies
The following antibodies were used: Gli1 (#2553S 
Cell Signaling, 1:1000), phospho-(Ser/Thr) AMPK 
Substrate (#5759 Cell Signaling, 1:1000), phospho-ACC 
(#3661S Cell Signaling, 1:2000), AMPK (07–181 
Millipore, 1:1000), Sufu (#C8IH7 Cell Signaling, 
1:1000), actin (sc-1616 SantaCruz 1:1000), tubulin 
(sc-8035 SantaCruz, 1:1000), laminin (sc-29012 SantaCruz, 
1:1000), phospho-Serine 408 (Eurogenetec, 1:1000), 
HA-probe (F-7) HRP (sc-7392 SantaCruz, 1:1000), 
anti-Flag-M2 (F1804 Sigma, 1:1000), anti-Flag-M2 
Peroxidase (A8592 Sigma, 1:5000).
Plasmids and site-directed mutagenesis
12xGli-Luc, TK-Renilla, PGEX4T1-Gli1 228–413, 
full-length PCDNA3Flag-Gli1 and mutant plasmids, 
PCDNA3Flag-Gli2, PCDNA3Flag-Gli3, PCDNA3Flag-
CRTC2, HA-Ub were previously described [28, 34, 36, 37]. 
HA-14-3-3 epsilon and Myc-AMPKα2 plasmids were 
purchased from Addgene. 
Gli1 S408A and S408E mutants were obtained 
using QuickChange II XL Site-Directed Mutagenesis 
Kit (Stratagene/Agilent®). Primers sequences used for 
mutagenesis reaction are listed below: 
Human Gli1 S408A Fw: 5′- CTGCCTCGGGC 
ACCAGCCATTTCTACAGTGGAG -3′; 
Human Gli1 S408A Rw: 5′- CTCCACTGTAGAAAT 
GGCTGGTGCCCGAGGCAG -3′;
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Human Gli1 S408E Fw: 5′- CTGCCTCGGGCACCA 
GAGATTTCTACAGTGGAG -3′; 
Human Gli1 S408E Rw: 5′- CTCCACTGTAGA 
AATCTCTGGTGCCCGAGGCAG -3′.
Statistical analysis
Statistical analysis was performed using StatView 
4.1 software (Abacus Concepts, Berkeley, CA). Data were 
expressed as mean +/− SD, and statistical differences 
between the means were analyzed by the Mann-Whitney 
U test for non-parametric values. P < 0.05 was considered 
statistically significant.
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